FY2029 Earnings Estimate for IN8bio Issued By HC Wainwright

IN8bio, Inc. (NASDAQ:INAB) – HC Wainwright upped their FY2029 earnings per share (EPS) estimates for shares of IN8bio in a research note issued on Friday, August 7th. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings per share of $0.32 for the year, up from their previous forecast of $0.27. HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for IN8bio’s current full-year earnings is ($1.23) per share.

IN8bio (NASDAQ:INAB) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($0.25) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.34) by $0.09.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of IN8bio in a research report on Friday, July 17th. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, IN8bio currently has a consensus rating of “Hold” and an average price target of $4.00.

IN8bio Trading Up 7.6%

INAB opened at $1.05 on Monday. IN8bio has a 1-year low of $0.90 and a 1-year high of $2.73. The stock’s fifty day simple moving average is $1.31 and its 200 day simple moving average is $1.55. The stock has a market cap of $10.35 million, a PE ratio of -0.65 and a beta of 0.24.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the business. HRT Financial LP acquired a new stake in shares of IN8bio in the fourth quarter valued at approximately $34,000. Captrust Financial Advisors bought a new stake in shares of IN8bio in the fourth quarter valued at approximately $43,000. Texas Capital Bank Wealth Management Services Inc acquired a new stake in IN8bio during the fourth quarter worth approximately $56,000. Citadel Advisors LLC acquired a new stake in IN8bio during the third quarter worth approximately $54,000. Finally, Two Sigma Investments LP acquired a new stake in IN8bio during the third quarter worth approximately $107,000. Institutional investors and hedge funds own 92.05% of the company’s stock.

Key Headlines Impacting IN8bio

Here are the key news stories impacting IN8bio this week:

• Positive Sentiment: HC Wainwright raised its FY2026 EPS estimate to a loss of $1.49 from $2.10 and its FY2027 estimate to a loss of $1.24 from $1.51. The firm also lifted estimates for IN8bio’s third and fourth quarters of 2026, suggesting expectations for lower operating losses. HC Wainwright raises IN8bio earnings estimates
• Positive Sentiment: The analyst improved quarterly 2027 forecasts, reducing expected losses to $0.33 per share in the first quarter, $0.34 in the second quarter, $0.35 in the third quarter and $0.22 in the fourth quarter. FY2028 estimates were also raised to a loss of $0.23 per share from $0.44, while the current full-year consensus calls for a $1.53 loss. IN8bio quarterly earnings estimate revisions
• Positive Sentiment: HC Wainwright’s longer-term model projects IN8bio reaching positive EPS of $0.64 in FY2030, providing a potential profitability narrative for investors focused on the company’s pipeline and long-term development prospects. IN8bio long-term earnings forecast
• Neutral Sentiment: A report stated that short interest was zero shares as of August 11, unchanged from July 27, with a zero-day days-to-cover ratio. Because both reported short-interest figures are zero, the claimed “significant increase” appears to be a data or calculation error and offers little useful trading insight.
• Negative Sentiment: HC Wainwright trimmed its FY2030 EPS forecast to $0.64 from $0.69. In addition, the estimates still imply substantial losses through FY2028, underscoring IN8bio’s continued dependence on clinical and commercial execution.

About IN8bio

IN8bio is a clinical-stage biopharmaceutical company developing γδ T cell therapeutic and γδ T cell engager (TCE) product candidates to address unmet medical needs. γδ T cells are
a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The Company’s lead programs consist of INB-100, an allogeneic γδ T cell candidate for adult patients with high-risk
leukemias undergoing haploidentical stem cell transplantation.